Sergey Tishkin
Research Subjects
Sergey Tishkin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kirichok
Enamine (Ukraine)
1 shared publication - Anatoly Soloviev
Enamine (Ukraine)
1 shared publication - Dmitry Granat
Enamine (Ukraine)
1 shared publication - Irina Shton
Enamine (Ukraine)
1 shared publication - Iryna Pishel
Enamine (Ukraine)
1 shared publication - Maria Sokolenko
Enamine (Ukraine)
1 shared publication
Latest Publications
- Open Access
- 28 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Replacement of a piperidine ring with aza-spirocycles reduces cardiotoxicity of a local anesthetic
Bupivacaine, a sodium ion channel inhibitor, has a long history of clinical use in local anesthesia and pain management. However, its systemic toxicity, which can lead to adverse cardiac conditions, poses a significant challenge in clinics. In this study, we replaced the central piperidine ring of bupivacaine with three linear spirocyclic moieties and evaluated the effects of the resulting analogues using physicochemical tests and animal studies. We found that, despite being more hydrophobic than the parent drug, the analogues demonstrated an acceptable level of local anesthesia in mice. Notably, the spirocyclic structures exhibited significantly lower toxicity, with increases in the lethal doses of 1.3-, 2.2-, and 5.0-fold for the three tested structures, respectively. Animal studies suggested that this reduced toxicity may be attributed to lower cardiotoxicity, as evidenced by less QRS widening in isolated guinea pig hearts. Our results suggest that further exploration of spirocyclic analogues of local anesthetics is warranted and support the use of spirocyclic azetidines as a replacement for the piperidine ring in drugs.
- 28 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessReplacement of a piperidine ring with aza-spirocycles reduces cardiotoxicity of a local anesthetic
Bupivacaine, a sodium ion channel inhibitor, has a long history of clinical use in local anesthesia and pain management. However, its systemic toxicity, which can lead to adverse cardiac conditions, poses a significant challenge in clinics. In this study, we replaced the central piperidine ring of bupivacaine with three linear spirocyclic moieties and evaluated the effects of the resulting analogues using physicochemical tests and animal studies. We found that, despite being more hydrophobic than the parent drug, the analogues demonstrated an acceptable level of local anesthesia in mice. Notably, the spirocyclic structures exhibited significantly lower toxicity, with increases in the lethal doses of 1.3-, 2.2-, and 5.0-fold for the three tested structures, respectively. Animal studies suggested that this reduced toxicity may be attributed to lower cardiotoxicity, as evidenced by less QRS widening in isolated guinea pig hearts. Our results suggest that further exploration of spirocyclic analogues of local anesthetics is warranted and support the use of spirocyclic azetidines as a replacement for the piperidine ring in drugs.